Baxter Recalls Brevibloc Injection Due to Discoloration
Baxter Healthcare Corp. recalls Brevibloc Double Strength Premixed Injection due to atypical yellow discoloration of the solution.
Recall notice
Discoloration: presence of atypical yellow discoloration of the solution .
Contact the company
What happened, in plain English
Baxter Healthcare Corp. is recalling a specific lot of Brevibloc Double Strength Premixed Injection because the solution may have an atypical yellow discoloration. The product is an Rx-only medication manufactured in Deerfield, Illinois. No other details regarding the cause or potential health effects are provided in this record. Read more at govinfonow.com/recall/43006-baxter-recalls-brevibloc-injection-due-to-discoloration.
Source Summary by GovInfoNow · govinfonow.com/recall/43006-baxter-recalls-brevibloc-injection-due-to-discoloration · Updated October 11, 2026 · FDA enforcement record: FDA #D-0852-2016
Cite this page
“Baxter Recalls Brevibloc Injection Due to Discoloration.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/43006-baxter-recalls-brevibloc-injection-due-to-discoloration. Based on FDA recall #D-0852-2016 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0852-2016%22&limit=1).
Why it’s dangerous
The hazard is described solely as the presence of atypical yellow discoloration in the solution. The record does not explain what this discoloration indicates or why it poses a danger to users.
Who’s affected
Patients or healthcare providers who possess the specific recalled lot of Brevibloc Double Strength Premixed Injection distributed nationwide. The record does not specify which patient groups are most at risk.
How to tell if you have this one
Check for Brevibloc Double Strength Premixed Injection, Esmolol Hydrochloride in Sodium Chloride, 2000mg/100mL (20 mg/mL), 100 mL. Look for NDC 10019-075-87 and Lot # C989954 with an expiration date of 9/17.
- Brand
Baxter Healthcare Corp.- Category
Drug
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 11 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0852-2016 (April 12, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0852-2016 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.